MiNK Therapeutics (INKT) Competitors $0.94 -0.07 (-7.33%) As of 03:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INKT vs. TELO, CRBU, TIL, TSVT, SGMT, CABA, SAVA, MCRB, SLDB, and JMACShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Telomir Pharmaceuticals (TELO), Caribou Biosciences (CRBU), Instil Bio (TIL), 2seventy bio (TSVT), Sagimet Biosciences (SGMT), Cabaletta Bio (CABA), Cassava Sciences (SAVA), Seres Therapeutics (MCRB), Solid Biosciences (SLDB), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Telomir Pharmaceuticals Caribou Biosciences Instil Bio 2seventy bio Sagimet Biosciences Cabaletta Bio Cassava Sciences Seres Therapeutics Solid Biosciences Maxpro Capital Acquisition Telomir Pharmaceuticals (NASDAQ:TELO) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations. Do analysts rate TELO or INKT? MiNK Therapeutics has a consensus price target of $6.50, indicating a potential upside of 559.90%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Telomir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TELO or INKT more profitable? MiNK Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -1,087.92% -806.34% MiNK Therapeutics N/A N/A -189.14% Which has preferable earnings and valuation, TELO or INKT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$13.07MN/AN/AMiNK TherapeuticsN/AN/A-$22.46M-$0.39-2.53 Does the media refer more to TELO or INKT? In the previous week, MiNK Therapeutics had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for MiNK Therapeutics and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.93 beat MiNK Therapeutics' score of -0.67 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MiNK Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do insiders and institutionals hold more shares of TELO or INKT? 2.9% of MiNK Therapeutics shares are owned by institutional investors. 20.6% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor TELO or INKT? MiNK Therapeutics received 15 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformTelomir PharmaceuticalsN/AN/AMiNK TherapeuticsOutperform Votes1575.00% Underperform Votes525.00% SummaryMiNK Therapeutics beats Telomir Pharmaceuticals on 9 of the 11 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.04M$3.00B$5.42B$9.21BDividend YieldN/A1.87%5.36%3.97%P/E Ratio-2.5345.0486.7517.45Price / SalesN/A298.681,296.9978.84Price / CashN/A191.4944.6537.70Price / Book-1.893.994.984.68Net Income-$22.46M-$40.99M$117.81M$224.54M7 Day Performance18.39%2.26%1.78%1.13%1 Month Performance100.53%0.17%3.16%3.88%1 Year Performance10.67%-2.88%25.83%21.57% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.4429 of 5 stars$0.94-7.3%$6.50+594.4%+13.3%$37.85MN/A-2.4530Stock SplitNews CoverageTELOTelomir PharmaceuticalsN/A$4.69-2.1%N/AN/A$138.87MN/A0.001CRBUCaribou Biosciences2.6111 of 5 stars$1.53-0.6%$10.33+575.4%-71.6%$138.54M$34.48M-0.93100Analyst RevisionTILInstil Bio2.5138 of 5 stars$20.97-2.1%$114.00+443.6%+80.4%$136.85MN/A-1.81410TSVT2seventy bio2.3581 of 5 stars$2.61+7.0%$9.00+244.8%-20.0%$134.65M$100.39M-1.40440SGMTSagimet Biosciences1.2898 of 5 stars$4.39+2.8%$23.00+423.9%-76.9%$134.64M$2M0.008CABACabaletta Bio3.0116 of 5 stars$2.74+12.8%$24.38+789.6%-87.6%$133.93MN/A-1.2750Analyst RevisionHigh Trading VolumeSAVACassava Sciences4.3046 of 5 stars$2.75+2.2%$111.50+3,954.5%-90.2%$132.30MN/A-1.9930MCRBSeres Therapeutics3.4591 of 5 stars$0.77+4.4%$5.08+562.4%-27.1%$131.02M$126.33M-3.34330Gap DownSLDBSolid Biosciences3.9787 of 5 stars$3.27+0.6%$15.30+367.9%-60.3%$130.67M$8.09M-1.08100Analyst RevisionNews CoverageJMACMaxpro Capital AcquisitionN/A$9.56+0.6%N/A+966.1%$128.37MN/A0.002,021Gap Up Related Companies and Tools Related Companies Telomir Pharmaceuticals Competitors Caribou Biosciences Competitors Instil Bio Competitors 2seventy bio Competitors Sagimet Biosciences Competitors Cabaletta Bio Competitors Cassava Sciences Competitors Seres Therapeutics Competitors Solid Biosciences Competitors Maxpro Capital Acquisition Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INKT) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
